NCT03989505COMPLETEDanonymous

Proenkephalin ANd Creatinine in the Prediction of Cardiac Contrast-Associated Kidney Events

Sponsor

Source record

Dr. med. Mahir Karakas

Phase

Source record

Not classified

Modality

AI-normalized

protein therapy

Target

AI-normalized

blood-draw for biomarker analyses

Indication / condition

AI-normalized

Contrast-induced Nephropathy

Intervention

Source record

blood-draw for biomarker analyses

Related intelligence directories

Indication directory: Contrast-induced Nephropathy Modality directory: protein therapy Target directory: blood-draw for biomarker analyses

Source & freshness

Source record

NCT ID

NCT03989505

Original source

ClinicalTrials.gov

Source last updated

May 18, 2022

Ingested at

May 22, 2026

Internal sync

May 23, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT03989505

Title

Proenkephalin ANd Creatinine in the Prediction of Cardiac Contrast-Associated Kidney Events

Sponsor

Dr. med. Mahir Karakas

Status

COMPLETED

Phase

Detailed source ingestion pending

Condition raw

Contrast-induced Nephropathy, Acute Kidney Injury, Coronary Artery Disease

Condition normalized

Contrast-induced Nephropathy, Acute Kidney Injury, Coronary Artery Disease

Modality raw

protein therapy

Modality normalized

protein therapy

Target raw

blood-draw for biomarker analyses

Target normalized

blood-draw for biomarker analyses

Interventions

blood-draw for biomarker analyses

Public preview

Source record

Currently, contrast-induced kidney injury cannot be diagnosed on the day of cardiac catheterization. Recently, proenkephalin (penKid) was introduced as a new glomerular filtration marker. The aim of this study is to investigate whether the change in penKid level allows for early detection of affected patients.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Proenkephalin ANd Creatinine in the Prediction of Cardiac Contrast-Associated Kidney Events

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 20, 2026

NCT ID

NCT03989505

Status

COMPLETED

Phase

N/A

Sponsor

Dr. med. Mahir Karakas

Executive brief

Investment-Ready Snapshot

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedMay 18, 2022

Internal syncMay 23, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT03989505

Indication

Contrast-induced Nephropathy

Modality

protein therapy

Target

blood-draw for biomarker analyses

Intervention

blood-draw for biomarker analyses

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.